Latest Press Releases Jun 11 2022 Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress Read More Jun 10 2022 Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Read More Jun 08 2022 Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 Read More Jun 08 2022 Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA Read More Jun 06 2022 Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions Read More Jun 02 2022 Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress Read More Load More Recent Media Library Items View All Date - Any -20212022 Tags Download LibraryImages Inclusion, Diversity and Equity at Vertex Fact Sheet Download 3 MB Date - Any -20212022 Tags Download LibraryImages Reshma Kewalramani, M.D. Chief Executive Officer and President Download 10 MB Date - Any -20212022 Tags Download LibraryImages Vertex International Headquarters Paddington – Lobby Padding reception entrance Download 915 KB Date - Any -20212022 Tags Download LibraryImages Vertex Logo with Tagline Download 2 MB | 2951 x 1952 Mediainfo@VRTX.com
Jun 11 2022 Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress Read More
Jun 10 2022 Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Read More
Jun 08 2022 Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 Read More
Jun 08 2022 Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA Read More
Jun 06 2022 Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions Read More
Jun 02 2022 Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress Read More
